CINVANTI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cinvanti, and when can generic versions of Cinvanti launch?
Cinvanti is a drug marketed by Heron Theraps Inc and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has nine patent family members in five countries.
The generic ingredient in CINVANTI is aprepitant. There are twenty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aprepitant profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cinvanti
A generic version of CINVANTI was approved as aprepitant by SANDOZ on September 24th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CINVANTI?
- What are the global sales for CINVANTI?
- What is Average Wholesale Price for CINVANTI?
Summary for CINVANTI
International Patents: | 9 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 92 |
Patent Applications: | 2,252 |
Drug Prices: | Drug price information for CINVANTI |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CINVANTI |
What excipients (inactive ingredients) are in CINVANTI? | CINVANTI excipients list |
DailyMed Link: | CINVANTI at DailyMed |
Paragraph IV (Patent) Challenges for CINVANTI
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CINVANTI | Intravenous Emulsion | aprepitant | 130 mg/18 mL | 209296 | 1 | 2022-04-29 |
US Patents and Regulatory Information for CINVANTI
CINVANTI is protected by ten US patents.
Patents protecting CINVANTI
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CINVANTI
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Merck Sharp & Dohme B.V. | Emend | aprepitant | EMEA/H/C/000527 Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. |
Authorised | no | no | no | 2003-11-11 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for CINVANTI
See the table below for patents covering CINVANTI around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2016044784 | ⤷ Sign Up | |
China | 106852118 | 阿瑞吡坦乳剂制剂 (Emulson formulations of aprepitant) | ⤷ Sign Up |
Japan | 2017533183 | アプレピタントのエマルジョン製剤 | ⤷ Sign Up |
South Korea | 20170056575 | 아프레피탄트의 에멀젼 제형 (EMULSION FORMULATIONS OF APREPITANT) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CINVANTI
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0734381 | PA2004002 | Lithuania | ⤷ Sign Up | PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111 |
0748320 | 08C0019 | France | ⤷ Sign Up | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
0734381 | 3/2004 | Austria | ⤷ Sign Up | PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111 |
0734381 | PA2004002,C0734381 | Lithuania | ⤷ Sign Up | PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |